On Tuesday, May 14, the pharmaceutical company Dr. Reddy's Laboratories Ltd announced a 66.58% rise in its net profit - the net income being Rs. 570.89 crore - for the quarter (which ended March 31, 2013).
Company analysts have attributed this meteorical rise in profit to robust sales across all departments of the firm.
Revenue for the three-month period gained 26%, arriving at a total of Rs. 3,340 crore, the company said in a statement.
The company's major departments include global generics, pharmaceutical services, and active pharma ingredients.
The company's other income in the quarter jumped to Rs. 163 crore in the months from January to March, compared to Rs. 20 crore in the previous year.
Profit was also boosted by a jump of nearly 40% in the net finance income at Rs. 40 crore. Its gross profit was up by 21%, thereby amounting to Rs. 1,684 crore.
The company said that its Board of Directors has recommended a final dividend of Rs. 15 per share for a face value of Rs. 5, for the financial year 2012-13.
In the fourth quarter, Dr. Reddy's launched 18 new generic products and filed for 14 new product registrations. (INN)